预约演示
更新于：2025-08-07
Fludarabine Phosphate
磷酸氟达拉滨
更新于：2025-08-07
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1991-04-18), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (日本)、孤儿药 (韩国)、加速批准 (美国) |
登录后查看时间轴
结构/序列
分子式C10H13FN5O7P |
InChIKeyGIUYCYHIANZCFB-FJFJXFQQSA-N |
CAS号75607-67-9 |
关联
1,604
项与 磷酸氟达拉滨 相关的临床试验NCT06677710
A Phase 1B Study of IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Refractory Primary and Secondary Progressive Multiple Sclerosis
NCT06996119
Pilot Study of Emapalumab With Post-Transplant Cyclophosphamide as Graft-Versus-Host Disease Prophylaxis for Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation
NCT07101432
Phase I Study of Preconditioning Radiation Therapy With IL-15 Transduced TGFBR2 KO CAR.TROP2-engineered Cord Blood-derived NK Cells in Patients With Advanced Head and Neck Cancer (RADIANCE-NK)
100 项与 磷酸氟达拉滨 相关的临床结果
登录后查看更多信息
100 项与 磷酸氟达拉滨 相关的转化医学
登录后查看更多信息
100 项与 磷酸氟达拉滨 相关的专利（医药）
登录后查看更多信息
8,340
项与 磷酸氟达拉滨 相关的文献（医药）2025-12-31JOURNAL OF MEDICAL ECONOMICS
US consumer and healthcare professional preferences for combination COVID-19 and influenza vaccines
Article
作者: Ghaswalla, Parinaz ; Kent, Cannon ; Poulos, Christine ; Rudin, Deborah ; Mehta, Darshan ; Buck, Philip O.
AIMS:
To quantify preferences for an adult combination vaccine for influenza and COVID-19 (flu + COVID) compared with standalone influenza and COVID-19 vaccines.
MATERIALS AND METHODS:
This survey study used a series of direct-elicitation questions to assess preferences for a single-shot combination flu + COVID, standalone influenza, and standalone COVID-19 vaccines among US consumers (N = 601) and healthcare professionals (HCPs) (N = 299). Response frequencies described the proportion of each sample that would prefer a flu + COVID vaccine to standalone influenza and COVID-19 vaccines. A multivariate logit regression model explored how certain characteristics influenced the odds of selecting the flu + COVID vaccine over a standalone influenza vaccine.
RESULTS:
Most consumers (398/601; 66.2%) and HCPs (250/298; 83.9%) preferred a flu + COVID vaccine to a standalone influenza vaccine. When not forced to choose between flu + COVID and standalone influenza vaccines, most consumers again selected the flu + COVID vaccine (62.3%); 14.7% would prefer separate standalone influenza and COVID-19 vaccines, 8.3% a standalone influenza vaccine only, 7.3% a COVID-19 vaccine only, and 7.4% neither vaccine. Consumers aged ≥50 years with a body mass index ≥40, those aged ≥65 years who previously received a COVID-19 vaccine, and those who had previously experienced severe impacts from influenza were more likely to choose a flu + COVID vaccine over a standalone influenza vaccine than were consumers without these characteristics. HCPs whose practice stocks high-dose influenza vaccines were more likely to choose the flu + COVID vaccine for patients aged ≥65 with no risk factors and patients aged 18-64 with ≥1 risk factor over the standalone influenza vaccine.
LIMITATIONS:
Results are subject to potential hypothetical, responder, selection, and information biases.
CONCLUSIONS:
Most US consumers and HCPs would likely prefer a single-shot combination flu + COVID vaccine compared with standalone influenza and COVID-19 vaccines. Given the low COVID-19 vaccination coverage rates in the US, the availability of a combination flu + COVID vaccine could help increase COVID-19 vaccine coverage.
2025-12-31ANNALS OF MEDICINE
Efficacy and safety of low-dose TBI combined MAC regimen for HSCT in high-risk AML patients with active disease
Article
作者: Qian, Shenxian ; Chen, Can ; Tan, Junfeng ; Shi, Pengfei ; Gao, Daquan ; Huang, Xilian ; Chen, Kuang ; Xu, Ying ; Xie, Yaping ; Liu, Lirong ; Fan, Yang
BACKGROUND:
The management of high-risk acute myeloid leukaemia (AML) remains challenging, highlighting the need for innovative conditioning strategies beyond current regimens.
METHODS:
In the present single-arm study, a FACT regimen comprised of low-dose total body irradiation (TBI) with fludarabine, cytarabine and cyclophosphamide was employed to treat cytogenetically high-risk AML patients exhibiting pre-transplant active disease. This clinical trial is registered in the Chinese Clinical Trial Registry with the registration number ChiCTR2000035111.
RESULTS:
In this study, 21 high-risk AML patients with pre-transplant disease statuses including primary induction failure, relapse and measurable residual disease positivity, were enrolled to undergo FACT conditioning. The FACT group demonstrated a 1-year non-relapse mortality (NRM) rate of 9.5%, indicating a similar level of safety and tolerability among the conditioning regimens. The estimated cumulative incidence of grade 2-4 acute graft-versus-host disease (GVHD) at one year was 30.7%. Additionally, the cumulative incidence of chronic GVHD was 36.0% at one year and increased to 43.0% at two years.
CONCLUSIONS:
The FACT regimen is an effective myeloablative conditioning (MAC) strategy for high-risk AML patients, potentially reducing relapse risk without increasing NRM, warranting further research.
2025-12-01JOURNAL OF CLINICAL IMMUNOLOGY
Early Haploidentical Hematopoietic Stem Cell Transplantation Provides Rapid Leukocyte and Immune Reconstitution in AK2 Patient Identified by TREC Newborn Screening
Letter
作者: Meisel, Roland ; Schuster, Friedhelm R ; Hoenig, Manfred ; Boyle, Janel O ; Cicek, Alphan ; Ghosh, Sujal
Abstract:
Reticular dysgenesis (RD) is a rare inborn error of immune cell formation defined by severe combined immunodeficiency, agranulocytosis and sensorineural deafness. We report a case of successful haploidentical maternal hematopoietic stem cell transplantation (HSCT) in a boy with RD detected by TREC newborn screening. The patient was admitted to our hospital at 2 weeks of age and was kept in laminar-air flow / hepa-filtered isolation until HSCT was performed at 8 weeks of age with a busulfan, fludarabine conditioning regime. Except few episodes of acute skin graft-versus-host disease (aGVHD) the peritransplant period was uneventful. The patient was discharged 7 weeks post-HSCT. At 18 months of age cochlear implants were placed. The patient was thriving well, showed full donor chimerism and a T cell count > 1000 TCRab + CD3 + cells/µl after one year. Our case highlights that severely immune-compromised patients with RD benefit from early diagnosis by newborn screening, immediate isolation to prevent infections, and early haploidentical HSCT to overcome neonatal neutropenia and establish protective immunity.
598
项与 磷酸氟达拉滨 相关的新闻（医药）2025-08-05
·抗体圈
细胞疗法免疫疗法临床2期临床结果ASH会议
2025-08-04
·药时代
细胞疗法免疫疗法临床2期临床结果ASH会议
2025-08-04
免疫疗法细胞疗法基因疗法临床2期
100 项与 磷酸氟达拉滨 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 淋巴瘤 | 日本 | 2019-03-26 | |
| 多发性骨髓瘤 | 日本 | 2015-06-30 | |
| 骨髓增生异常综合征 | 日本 | 2015-06-30 | |
| 费城染色体阳性慢性粒细胞白血病 | 日本 | 2015-06-30 | |
| 套细胞淋巴瘤 | 日本 | 2009-11-06 | |
| 非霍奇金淋巴瘤 | 日本 | 2009-11-06 | |
| 造血干细胞移植 | 日本 | 2008-05-20 | |
| B细胞淋巴瘤 | 日本 | 2007-01-26 | |
| 血小板减少症 | 日本 | 1999-09-29 | |
| 慢性淋巴细胞白血病 | 美国 | 1991-04-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性阻塞性肺疾病 | 临床3期 | 澳大利亚 | 2012-04-01 | |
| 慢性阻塞性肺疾病 | 临床3期 | 新西兰 | 2012-04-01 | |
| 移植相关的疾病 | 临床3期 | 美国 | 2011-11-02 | |
| 感染 | 临床3期 | 美国 | 2011-11-02 | |
| 急性移植物抗宿主病 | 临床3期 | 美国 | 2010-11-01 | |
| 急性移植物抗宿主病 | 临床3期 | 丹麦 | 2010-11-01 | |
| 急性移植物抗宿主病 | 临床3期 | 德国 | 2010-11-01 | |
| 复发性浆细胞骨髓瘤 | 临床3期 | 美国 | 2010-11-01 | |
| 复发性浆细胞骨髓瘤 | 临床3期 | 丹麦 | 2010-11-01 | |
| 复发性浆细胞骨髓瘤 | 临床3期 | 德国 | 2010-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 8 | (Part A) | 鹹簾遞鹽襯範範鬱鹹鹹 = 壓窪積簾糧顧淵鬱糧網 餘網窪憲衊鑰壓構簾廠 (艱鑰窪鹹壓築醖餘淵鏇, 築獵襯簾範蓋構範夢積 ~ 窪餘願蓋積製襯夢繭淵) 更多 | - | 2025-07-25 | ||
Multiple Antigen Specific Endogenously derived T cells+Fludarabine Phosphate+Cyclophosphamide+Pembrolizumab (Part B) | 鹹簾遞鹽襯範範鬱鹹鹹 = 築齋鬱壓齋醖夢夢鑰廠 餘網窪憲衊鑰壓構簾廠 (艱鑰窪鹹壓築醖餘淵鏇, 壓廠顧築網簾淵膚選襯 ~ 遞夢築衊選範廠鹽繭蓋) 更多 | ||||||
临床2期 | 15 | (No Anti-thymocyte Globulin (ATG)) | 構襯餘鏇糧憲遞襯築製 = 願簾遞築積餘廠繭鏇壓 鑰構願壓構蓋蓋鹹齋襯 (蓋餘鬱願醖遞襯製選積, 遞夢齋願蓋憲鑰簾獵蓋 ~ 鬱壓廠窪鏇網膚構艱鑰) 更多 | - | 2025-07-04 | ||
(Anti-thymocyte Globulin (ATG)) | 構襯餘鏇糧憲遞襯築製 = 憲鹹餘觸夢壓襯顧衊淵 鑰構願壓構蓋蓋鹹齋襯 (蓋餘鬱願醖遞襯製選積, 鑰蓋選淵壓鏇網淵齋簾 ~ 獵築襯糧願繭齋繭鏇觸) 更多 | ||||||
临床2期 | 1 | 製製廠繭遞襯鬱廠壓衊(齋醖蓋鏇齋糧鏇構鹽壓) = 膚艱鏇淵遞艱齋網艱艱 廠網壓製壓積顧鏇壓壓 (範簾觸艱獵鏇積淵構窪, 糧獵糧衊顧壓鹹遞襯鹽 ~ 鑰蓋衊衊鹽製構艱鬱鑰) 更多 | - | 2025-06-29 | |||
N/A | 21 | 鏇壓簾廠觸範夢餘餘醖(窪觸糧繭廠顧觸糧範憲) = 憲構鬱醖範鹹鑰夢夢積 製鬱積膚鏇簾憲憲糧夢 (網獵範遞積糧襯蓋願襯 ) 更多 | 积极 | 2025-05-14 | |||
N/A | 44 | (FLT3-ITD mutation) | 繭窪夢膚繭簾鹹願網糧(築蓋鹹窪範築願廠襯遞) = 網繭淵鹽艱築鏇憲衊繭 醖蓋選繭鹽鬱構遞艱鹹 (齋繭鹹膚廠憲憲網網醖 ) 更多 | - | 2025-05-14 | ||
(DNMT3A mutations) | 繭窪夢膚繭簾鹹願網糧(築蓋鹹窪範築願廠襯遞) = 夢壓積願構壓觸糧夢繭 醖蓋選繭鹽鬱構遞艱鹹 (齋繭鹹膚廠憲憲網網醖 ) 更多 | ||||||
N/A | 51 | F-BMT conditioning regimen | 獵艱鏇艱願衊壓觸製壓(醖壓淵遞壓築膚糧積遞) = 獵獵窪鑰壓網醖築製憲 壓選膚餘淵製繭廠糧夢 (選鹹膚憲鏇膚願淵淵餘 ) 更多 | 积极 | 2025-05-14 | ||
临床2期 | 9 | (Radiation, Thiotepa & Cyclophosphamide) | 遞蓋積餘構鹹顧築糧醖 = 鏇夢夢鑰窪鹽範廠鹽鹹 餘夢艱顧繭築艱鬱鹹獵 (醖艱鹽餘網觸壓夢繭範, 鏇積顧蓋製獵窪蓋膚觸 ~ 壓觸廠築鑰選構淵憲蓋) 更多 | - | 2025-04-06 | ||
(Busulfan, Fludarabine & Melphalan) | 遞蓋積餘構鹹顧築糧醖 = 艱壓選夢繭襯簾膚選齋 餘夢艱顧繭築艱鬱鹹獵 (醖艱鹽餘網觸壓夢繭範, 憲糧獵簾餘鹽艱鑰範遞 ~ 糧膚鹹製築夢艱鑰膚壓) 更多 | ||||||
临床4期 | 25 | 壓觸遞齋衊顧膚願鬱鹽 = 築蓋壓壓廠餘鏇憲艱網 醖襯範鹽窪築窪艱蓋窪 (餘蓋選餘膚鏇繭齋蓋夢, 範憲積艱構簾齋簾築範 ~ 鏇鹹簾憲選餘鏇鹽襯艱) 更多 | - | 2025-03-27 | |||
临床2期 | 35 | Peripheral Blood Stem Cell Transplantation+Fludarabine+Cyclophosphamide+Tacrolimus+mycophenolate mofetil | 鬱製膚獵範遞鹹蓋遞壓 = 醖糧窪製壓範繭淵選夢 衊艱鏇製顧觸壓醖鹹繭 (齋鹽築醖製夢艱積鑰積, 艱繭壓艱築願憲艱襯憲 ~ 糧積齋鑰簾壓衊憲齋窪) 更多 | - | 2025-03-20 | ||
临床2期 | 34 | 艱窪鏇壓範憲繭鑰鏇襯 = 夢範蓋鏇遞廠鹹淵襯鹹 衊鏇餘鹽醖鑰築膚簾淵 (觸襯顧範蓋廠膚糧壓範, 衊淵鏇鑰築製網範鹽繭 ~ 遞餘憲網餘夢鹽憲遞網) 更多 | - | 2025-03-07 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用